BC Extra | Sep 18, 2019
Preclinical News

Storm shows PoC for RNA epigenetic inhibitor as field moves toward clinic

Storm Therapeutics unveiled what it called the first in vivo proof-of-concept data for a small molecule inhibitor of an RNA epigenetic enzyme. Data were presented Wednesday at the inaugural RNA Epigenetics in Human Disease Conference...
BC Innovations | Jul 19, 2019
Tools & Techniques

A mark up for RNA epigenetics

As a field, RNA epigenetics is still in its infancy, though picking up pace as researchers translate lab findings to drug development. Two papers straddling academia and industry provide a new quantitative method that can...
BC Innovations | Mar 3, 2016
Distillery Therapeutics

Therapeutics: Methyltransferase like 3 (METTL3); METTL14

Infectious disease INDICATION: HIV / AIDs Cell culture studies suggest inhibiting METTL3 or METTL14 could help treat HIV / AIDS. In HIV-infected human CD4+ T cells, shRNA targeting METTL3 or METTL14 decreased levels of HIV...
Items per page:
1 - 3 of 3